Related Experiment Video
Updated: Oct 1, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
Published on: April 29, 2014
Low activity of 13-cis-retinoic acid plus interferon alpha 2a in advanced renal cell carcinoma
Alejandro V Jaremtchuk1, Enrique F Aman, Walter Ponce
1GETICS (Grupo de Estudio Tratamiento e Investigación del Cáncer, del Sur). Clinica Santa Lucía, Comodoro Rivadavia, Argentina.
Abstract:
Retinoids and interferon alpha have shown synergistic activity against metastatic renal cell carcinoma in previous preclinical and clinical studies. Based on these results, we conducted a phase II trial of 13-cis-retinoic acid (cRA) at 1 mg/kg/dose interferon alpha2a (IFN) at initial dose of 9 MU three times a week. Thirty-one patients were entered, all evaluable for toxicity and 30 evaluable for response. One patient achieved a partial response and 10 patients achieved stable disease. Toxicity was mild and primarily related to interferon. No toxic deaths were reported. Median survival time was 10 months. At the dose and schedule used, cRA and interferon-alpha2a showed low activity against metastatic renal cell carcinoma. Further studies with this combination are not recommended.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
The Retinoblastoma Gene
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...
Inhibition of Cdk Activity